中国的一项研究发现,carboplatin可增加三联阴性乳腺癌患者的存活率,且没有新的安全问题。 A Chinese study found carboplatin boosts survival for triple-negative breast cancer patients with no new safety issues.

由富丹大学上海癌症中心领导的一项大型中国研究发现,在标准治疗中增加了碳白素,大大改善了三阴乳腺癌患者的存活率,治疗组的三年无复发性存活率为92.3%,控制组为85.8%,癌症复发风险降低36%。 A large Chinese study led by Fudan University Shanghai Cancer Center found adding carboplatin to standard treatment significantly improved survival for triple-negative breast cancer patients, with a 92.3% three-year recurrence-free survival rate in the treated group versus 85.8% in the control group, and a 36% lower risk of cancer returning. 高风险病人的三年存活率达到98%。 High-risk patients saw a 98% three-year survival rate. 治疗没有显示出新的安全关切,支持了手术后向个性化护理的转变。 The treatment showed no new safety concerns and supports a shift toward personalized care after surgery. 研究结果发表在BMJ上。 Results were published in BMJ.